With medical oncology trials placed on maintain throughout the COVID-19 pandemic, researchers turned to troves of knowledge to seek out sufferers throughout the nation who would qualify for trials, even when they weren’t bodily there.
Synthetic intelligence enabled this course of, and should have created a transfer towards decentralized trials that probably might final lengthy after the pandemic is over.
Jeff Elton is CEO of ConcertAI, which works with among the largest oncology pharmaceutical corporations and analysis organizations. Healthcare IT Information interviewed Elton to get his ideas on this shift and what it means for each therapies and affected person outcomes.
Q: With trials on maintain, researchers have been working with all of this knowledge to seek out sufferers who would qualify for trials, even when they don’t seem to be bodily there. How did synthetic intelligence know-how allow this?
A: By placing the info in most cancers facilities to work. We course of structured and unstructured knowledge – combing by means of EHRs in addition to different sources of affected person info that EHRs may not embrace. Pure language processors and different instruments integral to workflows are vital right here.
The medical settings have mountains of knowledge. When participation